GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck & Co crashed the party.

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

This guest essay reflects the views of Dr. Richard Barakat, physician-in-chief at the Northwell Health Cancer Institute.

One especially frightening type of cancer that is extremely difficult to detect and seems to show up more often in Black ...

A miscarriage would lead to her diagnosis. “They said, ‘Don’t worry. Women under 40 do not get uterine cancer. It’s not a concern. It’s probably just a pre-cancer,'" Allen told NBC6.

Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially ...

Uterine fibroid pain treatments like medications or surgery can offer relief. Uterine fibroid pain originates from non-cancerous tumors that grow in a person's uterus. The growths vary in size and ...

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...

Gynecological cancers—including ovarian, uterine, cervical, vaginal and vulvar cancers—pose a significant health burden for women. While lifestyle and environmental factors contribute to cancer risk, ...